ALAUNOS THERAPEUTICS INC
TCRTNASDAQ🏆 #3759 by market capUS Equity
$1.97▼ $0.02 (−1.01%)
Live1h—
24h▼ 1.0%
7d▲ 3.1%
14d▲ 2.6%
30d▼ 3.9%
1y▼ 23.6%
🏦Market Cap
$5M
Small Cap
📈Revenue Growth (YoY)
-70.0%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
952.4x
Expensive
Otter Score
68
Fair
Trading Snapshot
- Day Range
- $1.96 – $2.00
- 52-Week Range
- $1.67 – $4.59
- Volume
- $5.83B
- Avg Volume
- $5.25B
- Shares Outstanding
- 2.4M
- Next Earnings
- Oct 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $5,077
- Last Q Revenue
- $1,177
- P/E Ratio
- —
- P/S Ratio
- 952.4x
- EPS (TTM)
- $-2.06
- Dividend Yield
- —
Why Investors Own TCRT
- ✓High-growth profile — revenue up +57.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 56% gross margin and 28% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$5,077▲ +64.5% YoY
Gross Margin (TTM)
55.5%▲ +4.4% YoY
Operating Income (TTM)
$1,640▲ +64.5% YoY
Free Cash Flow (TTM)
$1,401▲ +64.5% YoY
About ALAUNOS THERAPEUTICS INC
A company profile for ALAUNOS THERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
68/100
Analyst Ratings
ⓘConsensus
Sell
6 analysts
Strong Buy0
Buy0
Hold3
Sell1
Strong Sell2
Ratings as of Mar 2025
Latest News & Updates
🚀
CNBC·2h ago
ALAUNOS THERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
CNBC·5h ago
Analysts lift TCRT price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
Bloomberg·1d ago
ALAUNOS THERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.